Compare Essex Property Trust, Inc. (ESS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Novartis AG — how do they compare? Essex Property Trust, Inc. trades at $297.74 (market cap $18.82B), while Novartis AG trades at $152.08 (market cap $287.66B). The key difference: Novartis AG is far larger — about 15.3× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.54%). Which is the better fit depends on your goals.
| ESS | NVS | |
|---|---|---|
Market Cap | $18.82B | $287.66B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $168.62 |
52-Week Low | $239.61 | $113.50 |
Enterprise Value | $25.54B | $327.68B |
Dividend Yield | 3.54% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Essex Property Trust (ESS) trades at $293.32, down 1.61% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 30.03% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and inclusion in the Russell Microcap Index, reflecting positive momentum.
The outlook for ESS is cautiously optimistic, driven by robust West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts maintain a mixed consensus with a $294.25 price target, suggesting limited near-term upside from current levels amid balanced sentiment.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
